Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 4/20 | 0.65 |
| ▸ | PIM1 | P11309 | 4/20 | 0.65 |
| ▸ | PRKACA | P17612 | 4/20 | 0.65 |
| ▸ | CLK2 | P49760 | 4/20 | 0.65 |
| ▸ | GSK3B | P49841 | 4/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.65 |
| ▸ | CDK2 | P24941 | 4/20 | 0.65 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.65 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.65 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.65 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.65 |
| ▸ | PRKX | P51817 | 3/20 | 0.65 |
| ▸ | FLT3 | P36888 | 3/20 | 0.65 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.65 |
| ▸ | STK3 | Q13188 | 3/20 | 0.65 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.65 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.65 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.65 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1851228 | 0.92 | CDK9 (0.68) | MAP4K4PIM1PRKACACLK2GSK3B | |
| SCHEMBL1850762 | 0.91 | CHEK1 (0.65) | MAP4K4PIM1PRKACACLK2GSK3B | |
| SCHEMBL27819456 | 0.91 | CDK9 (0.64) | MAP4K4PIM1PRKACACLK2GSK3B | |
| SCHEMBL1851852 | 0.91 | ROCK1 (0.71) | MAP4K4PIM1PRKACACLK2GSK3B | |
| SCHEMBL1849976 | 0.89 | CHEK1 (0.69) | MAP4K4PIM1PRKACACLK2GSK3B | |
| SCHEMBL1850935 | 0.89 | CHEK1 (0.59) | MAP4K4PIM1PRKACACLK2GSK3B | |
| SCHEMBL1848237 | 0.88 | CHEK1 (0.64) | MAP4K4PIM1PRKACACLK2GSK3B | |
| SCHEMBL1850294 | 0.88 | CHEK1 (0.64) | MAP4K4PIM1PRKACACLK2GSK3B | |
| SCHEMBL1853607 | 0.88 | CHEK1 (0.64) | MAP4K4PIM1PRKACACLK2GSK3B | |
| SCHEMBL1850620 | 0.88 | CHEK1 (0.64) | MAP4K4PIM1PRKACACLK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323659-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2011-05-25 | — | — | EP | claimed |
| WO-2010017150-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | WO | claimed |
| US-20100035919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| CN-102170883-A | Compounds useful as inhibitors of protein kinases | ABBOTT LAB | 2011-08-31 | — | — | CN | disclosed |
| EP-2323659-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010017150-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | ROCK1, ROCK2, RHOA | MAP4K4 105/4885PIM1 820/4885PRKACA 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.